Gilead Sciences (GILD) PT Raised to $76 at Truist Securities as Generic Patent Challenges Settled
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas raised the price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $71.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
